UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) August 5, 2003

 

BioMarin Pharmaceutical Inc.

---

(Exact name of registrant as specified in its charter)

 

Delaware		000-26727		68-0397820
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

 

371 Bel Marin Keys Boulevard, Suite 210, Novato, California				94949
(Address of principal executive offices)				(Zip Code)

 

Registrant’s telephone number, including area code (415) 884-6700

 

Not Applicable

---

(Former name or former address, if changed since last report)

 

---

Item 7.    Financial Statements and Exhibits.

 

(a)

Financial Statements of Business Acquired.

 

Not Applicable.

 

(b)

Pro Forma Financial Information.

 

Not Applicable.

 

(c)

Exhibits.

 

Exhibit 99.1

Press Release of BioMarin Pharmaceutical Inc. (the “Registrant”) dated August 5, 2003.

 

Item 12.    Results of Operations and Financial Condition.

 

On August 5, 2003, Registrant announced financial results for its second quarter and six months ended June 30, 2003. The Registrant’s press release issued on August 5, 2003 is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information in this report is to be considered filed under the Exchange Act.

---

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

		BioMarin Pharmaceutical Inc., a Delaware corporation (Registrant)
Date            August 5, 2003		/s/    LOUIS DRAPEAU         Louis Drapeau Chief Financial Officer

---

EXHIBIT INDEX

 

Exhibit No.		Description
Exhibit 99.1		Press Release of the Registrant dated August 5, 2003